Skip to main content
. 2015 Sep 30;20(11):1253–1260. doi: 10.1634/theoncologist.2015-0151

Table 3.

The univariate and multivariate Cox regression analyses for overall survival and progression-free survival in patients with metastatic clear cell renal cell carcinoma receiving vascular endothelial growth factor-tyrosine kinase inhibitor treatment

graphic file with name theoncologist_15151t3.jpg